Emergent BioSolutions Inc. (NYSE:EBS) Holdings Lowered by Cetera Investment Advisers

Cetera Investment Advisers lessened its position in Emergent BioSolutions Inc. (NYSE:EBS - Free Report) by 27.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 277,247 shares of the biopharmaceutical company's stock after selling 107,236 shares during the period. Cetera Investment Advisers owned about 0.51% of Emergent BioSolutions worth $2,650,000 as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. American Century Companies Inc. grew its holdings in Emergent BioSolutions by 23.4% in the fourth quarter. American Century Companies Inc. now owns 2,137,712 shares of the biopharmaceutical company's stock valued at $20,437,000 after purchasing an additional 404,667 shares during the period. Invesco Ltd. grew its holdings in Emergent BioSolutions by 70.9% in the fourth quarter. Invesco Ltd. now owns 1,539,907 shares of the biopharmaceutical company's stock valued at $14,722,000 after purchasing an additional 638,995 shares during the period. Dimensional Fund Advisors LP grew its holdings in Emergent BioSolutions by 67.5% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,104,058 shares of the biopharmaceutical company's stock valued at $10,554,000 after purchasing an additional 444,790 shares during the period. Connor Clark & Lunn Investment Management Ltd. grew its holdings in Emergent BioSolutions by 8.3% in the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 902,332 shares of the biopharmaceutical company's stock valued at $8,626,000 after purchasing an additional 69,157 shares during the period. Finally, Assenagon Asset Management S.A. grew its stake in Emergent BioSolutions by 3.4% during the fourth quarter. Assenagon Asset Management S.A. now owns 766,537 shares of the biopharmaceutical company's stock worth $7,328,000 after buying an additional 24,985 shares during the period. Institutional investors and hedge funds own 78.40% of the company's stock.

Analyst Ratings Changes

Several research firms have issued reports on EBS. HC Wainwright reiterated a "buy" rating and set a $15.00 price objective on shares of Emergent BioSolutions in a research note on Tuesday, April 1st. Wall Street Zen downgraded shares of Emergent BioSolutions from a "buy" rating to a "hold" rating in a research note on Wednesday, March 5th.

Emergent BioSolutions Stock Performance

Shares of NYSE:EBS traded down $0.10 during trading on Friday, hitting $6.40. 1,179,900 shares of the company traded hands, compared to its average volume of 1,854,243. The company has a quick ratio of 1.47, a current ratio of 2.88 and a debt-to-equity ratio of 1.30. The business's fifty day moving average is $5.24 and its 200-day moving average is $7.71. The stock has a market capitalization of $347.38 million, a price-to-earnings ratio of -1.56 and a beta of 2.09. Emergent BioSolutions Inc. has a one year low of $4.02 and a one year high of $15.10.

Emergent BioSolutions (NYSE:EBS - Get Free Report) last issued its quarterly earnings data on Wednesday, May 7th. The biopharmaceutical company reported $0.71 EPS for the quarter, topping analysts' consensus estimates of $0.49 by $0.22. Emergent BioSolutions had a negative return on equity of 9.91% and a negative net margin of 18.55%. The firm had revenue of $222.20 million during the quarter, compared to the consensus estimate of $218.50 million. As a group, equities analysts predict that Emergent BioSolutions Inc. will post -0.63 earnings per share for the current fiscal year.

Emergent BioSolutions declared that its Board of Directors has initiated a share buyback program on Monday, March 31st that allows the company to buyback $50.00 million in shares. This buyback authorization allows the biopharmaceutical company to buy up to 19% of its stock through open market purchases. Stock buyback programs are often a sign that the company's board believes its stock is undervalued.

Insider Transactions at Emergent BioSolutions

In related news, Director Neal Franklin Fowler sold 35,000 shares of the stock in a transaction that occurred on Wednesday, March 12th. The stock was sold at an average price of $5.83, for a total value of $204,050.00. Following the completion of the transaction, the director now directly owns 101,100 shares of the company's stock, valued at $589,413. This represents a 25.72% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Insiders own 3.20% of the company's stock.

Emergent BioSolutions Company Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.